Cyclophosphamide was also formerly known as the brand name Cytoxan.
Cyclophsophamide is given either intravenously (IV) or orally for pulmonary fibrosis. Studies for both treatments have been completed and some studies are still on-going. Each treatment has its advantages and disadvanatges to the patient. As with all treatments for scleroderma, patients respond differently to oral and IV cyclophosphamide treatments.
Correlation of Cough With Disease Activity and Treatment With Cyclophosphamide in Scleroderma Interstitial Lung Disease (SSc-ILD). Findings from the Scleroderma Lung Study. Cough is a common symptom in SSc-ILD and correlates with the extent of fibrosis. It may be a symptom of ongoing fibrosis. CHEST Journal. (Also see Lung Involvement)
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) (SLSII). The purpose of this study is to determine whether people with symptomatic scleroderma-related interstitial lung disease experience more respiratory benefits from treatment with a 2-year course of mycophenolate mofetil or treatment with a 1-year course of oral cyclophosphamide. ClinicalTrials.gov.
Long-term follow-up of patients with scleroderma interstitial lung disease (SSc-ILD) treated with intravenous cyclophosphamide(CYC) pulse therapy: a single–center experience. In patients with ILD-SSc, CYC stabilized the reduction of FVC during treatment, but this effect was not persistent. The vascular characteristic of ILD-SSc (DLCO) was not affected by CYC treatment. PubMed, Isr Med Assoc J, 2015 Mar;17(3):150-6.
Low-dose pulse cyclophosphamide (CYC) in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders. Our study supports the use of low-dose pulse CYC as induction therapy of recently deteriorated SSc-ILD. PubMed, Semin Arthritis Rheum, 2015 Feb;44(4):437-44.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: